<DOC>
	<DOCNO>NCT00748436</DOCNO>
	<brief_summary>The purpose study examine effect betahistine body weight obese female subject</brief_summary>
	<brief_title>Efficacy Study Betahistine Body Weight Obese Female Subjects</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , dose finding , multicenter study . The study consist 3 treatment group ( 48 mg/day , 96 mg/day , match placebo ) . Approximately 180 subject ( 60 per treatment group ) randomize 12-week study . A screening visit use determine subject suitability inclusion trial . One week screen visit subject meet inclusion criterion none exclusion criterion randomly assign 1 follow treatment group : - Betahistine 24 mg twice day ( BID ) ( 48 mg/day total ) , - Betahistine 48 mg BID ( 96 mg/day total ) , - Matching placebo . All subject prescribe nutritionally balance mildly hypocaloric diet . The prescribed diet contain approximately 30 % calorie fat , 50 % calorie carbohydrates , 20 % calorie protein . The individual subject 's estimate total daily energy expenditure minus 600 kcal use determine subject 's daily caloric intake value study . The total daily energy expenditure estimate subject basal energy expenditure multiply correction factor 1.3 account amount energy need mild moderate daily activity obese subject . Double-blind treatment continue 12 week . Study medication ( betahistine and/or match placebo ) orally administer BID 1-2 hr prior meal ( 10:00 17:00 ) . During period , 4 additional study visit ( 2 , 4 , 8 , 12 week ) take place .</detailed_description>
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Betahistine</mesh_term>
	<criteria>Signed write informed consent Female subject 18 50 year age Premenopause Obese BMI 30 kg/m2 40 kg/m2 Has obese least one year prior screen Nonlactating Nonpregnant ; negative urine pregnancy test result , plan become pregnant study willing continue practice appropriate birth control ( implant , injectables , oral contraceptive , intrauterine contraceptive device , sexual abstinence , tubal ligation , vasectomized partner ) entire study duration . Has obesity know endocrine origin ( e.g. , Cushing 's disease , Addison 's disease , hypothalamic tumor ) ; Has medical history ( e.g. , morbid childhood obesity ) and/or physical characteristic ( e.g. , polydactyly ) suggestive genetic obesity ( e.g. , ob/ob genotype ) syndromatic obesity ( e.g. , PraderWilli syndrome , Bardet Biedl syndrome ) ; Previous surgical procedure weight loss ; Has liposuction within 1 year screen plan liposuction study ; History bulimia evidence laxative abuse ; Has body weight loss 4 kg 90 day prior screen ; Has take drug capable influence body weight 30 day prior screen ; Has recently ( &lt; 6 month prior screen ) start plan start smoke cessation program ; Has major change daily physical activity ( e.g. , initiation exercise program ) start weight loss program within 90 day prior screen ; Has clinically significant history presence follow condition : Active past history cardiovascular cerebrovascular disease include unstable angina , myocardial infarction , transient ischemic attacks/stroke , clinically significant arrhythmia , congestive heart failure , cardiac valve abnormality ; Type 1 diabetes mellitus ; Type 2 diabetes mellitus treatment metformin monotherapy and/or diet HbA1c &gt; 8 % ; Severe type 2 diabetes history ketoacidosis diabetic ulcer , presence retinopathy , neuropathy , nephropathy ; Renal insufficiency define serum creatinine equal high 1.5 mg/dL ( 133 Âµmol/L ) screening ; Malignant disease within 5 year screen ; Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) high 2 x ULN ; Thyroidstimulating hormone ( TSH ) outside normal range ; Plans surgery ( elective otherwise ) course study ; Has uncontrolled hypertension ( sit blood pressure &gt; 160/95 mmHg screen randomization ) , uncontrolled hyperlipidemia ( triglycerides [ TG ] &gt; 400 mg/dL lowdensity lipoprotein cholesterol [ LDLC ] &gt; 190 mg/dL ) , uncontrolled diabetes ( HbA1c &gt; 8 % ) ; History asthma ; History peptic ulcer associate gastrointestinal bleeding require treatment H2 blocker proton pump inhibitor last 12 month . Has undergone bilateral Ovarectomy . History HIV Has clinical laboratory test value ( chemistry , hematology , urinalysis ) judge clinically significant investigator ; Has physical examination electrocardiogram ( ECG ) significant abnormality , judge investigator ; Currently abuse drug alcohol history abuse investigator 's opinion could cause subject noncompliant study procedure ; Has psychiatric neurological disorder require chronic medication ( e.g. , antidepressant ) and/or subject score &gt; 8 The Harvard Department Psychiatry National Depression Screening Day Scale ( THE HANDS ) ( mean `` Presence major depressive episode likely. '' ) . Chronic need use antihistamine ; Has stable treatment regimen follow medication minimum 90 day prior screen : Oral contraceptive ; Antihypertensive agent ; Metformin ; Lipidlowering agent ; Thyroid replacement therapy ; Has treat past 60 day , currently treat , expect require undergo treatment follow excluded medication ; All prescription overthecounter agent take purpose weight reduction , include ( limit ) follow anti obesity agent : Prescription drug orlistat , sibutramine , rimonabant phentermine ; Overthecounter antiobesity agent ( e.g. , herbal supplement alternative remedy ) ; Psychotropic/neurological agent include follow : Antipsychotic agent ( e.g. , olanzapine , clozapine , risperidol , lithium , etc. ) . Antiepileptic agent ( e.g. , topiramate , zonisimide , valproate , carbamazepine ) ; Antidepressant agent include follow : monoamine oxidase inhibitor , bupropion , tricyclic antidepressant , tetracyclic antidepressant ; selective serotonin reuptake inhibitor ( e.g. , Fluoxetine , bupropion ) ; Systemic steroid administer oral , intravenous , intramuscular route ; Drugs directly affect gastrointestinal motility ( e.g. , metoclopramide , chronic [ take 10 day within 6 month period ] macrolide antibiotic erythromycin new derivative ) ; Calcitonin ; Insulin ; Exenatide ; Sulfonylureas ; Meglitinides Has receive investigational drug within 90 day screen ; Receipt investigational treatment ( drug device ) within 90 day prior screen ; Is immediate family member personnel directly affiliate study investigative site , personally directly affiliate study investigative site ; Is employ OBEcure Ltd .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Obese female</keyword>
	<keyword>Weight loss</keyword>
	<keyword>Betahistine</keyword>
</DOC>